{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:38:57Z","timestamp":1790962737617,"version":"4.1.0"},"reference-count":20,"publisher":"SAGE Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2018,12,12]]},"DOI":"10.3233\/jad-180675","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T12:47:56Z","timestamp":1541508476000},"page":"1409-1424","source":"Crossref","is-referenced-by-count":34,"title":["Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies"],"prefix":"10.1177","volume":"66","author":[{"given":"H. Robert","family":"Brashear","sequence":"first","affiliation":[{"name":"Janssen Alzheimer Immunotherapy Research & Development, LLC, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nzeera","family":"Ketter","sequence":"additional","affiliation":[{"name":"Janssen Alzheimer Immunotherapy Research & Development, LLC, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Bogert","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Raritan, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Di","sequence":"additional","affiliation":[{"name":"Janssen Alzheimer Immunotherapy Research & Development, LLC, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Salloway","sequence":"additional","affiliation":[{"name":"Brown Medical School, Butler Hospital, Blackstone Blvd., Providence, RI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reisa","family":"Sperling","sequence":"additional","affiliation":[{"name":"Center for Alzheimer Research and Treatment, Brigham and Women\u2019s Hospital, MA, USA; General Hospital, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-180675_ref1","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-180675_ref2","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"key":"10.3233\/JAD-180675_ref3","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.2337\/dc09-2315","article-title":"The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy","volume":"33","author":"Rosenstock","year":"2010","journal-title":"Diabetes Care"},{"key":"10.3233\/JAD-180675_ref4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: A retrospective analysis","volume":"11","author":"Sperling","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-180675_ref5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-180675_ref6","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2012","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-180675_ref7","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/cpt.200","article-title":"Current thinking on the mechanistic basis of Alzheimer\u2019s and implications for drug development","volume":"98","author":"Ising","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.3233\/JAD-180675_ref8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nbt0215-115","article-title":"Pivotal trials for beta-secretase inhibitors in Alzheimer\u2019s","volume":"33","author":"Sheridan","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.3233\/JAD-180675_ref9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1586\/17512433.2015.1034690","article-title":"What lessons can be learned from failed Alzheimer\u2019s disease trials?","volume":"8","author":"Toyn","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.3233\/JAD-180675_ref10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00401-009-0498-z","article-title":"Microvasculature changes and cerebral amyloid angiopathy in Alzheimer\u2019s disease and their potential impact on therapy","volume":"118","author":"Weller","year":"2009","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-180675_ref11","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.3174\/ajnr.A3500","article-title":"MR imaging features of amyloid-related imaging abnormalities","volume":"34","author":"Barakos","year":"2013","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.3233\/JAD-180675_ref12","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3233\/JAD-160216","article-title":"Central review of amyloid-related imaging abnormalities in two phase III clinical trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease patients","volume":"57","author":"Ketter","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-180675_ref13","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/j.jalz.2012.11.010","article-title":"Vascular alterations in PDAPP mice after anti-Abeta immunotherapy: Implications for amyloid-related imaging abnormalities","volume":"9","author":"Zago","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-180675_ref14","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.bbadis.2010.05.004","article-title":"Murine models of Alzheimer\u2019s disease and their use in developing immunotherapies","volume":"1802","author":"Wisniewski","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.3233\/JAD-180675_ref15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","article-title":"Bapineuzumab for mild to moderate Alzheimer\u2019s disease in two global, randomized, phase 3 trials","volume":"8","author":"Vandenberghe","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-180675_ref16","doi-asserted-by":"crossref","first-page":"S44.002.","DOI":"10.1212\/WNL.80.7_supplement.S44.002","article-title":"Clinical correlates of amyloid-related imaging abnormalities (ARIA) in phase 3 studies of bapineuzumab in Alzheimer\u2019s disease (AD) (S44.002)","volume":"80","author":"Sperling","year":"2013","journal-title":"Neurology"},{"key":"10.3233\/JAD-180675_ref17","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3174\/ajnr.A3475","article-title":"An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion","volume":"34","author":"Barkhof","year":"2013","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.3233\/JAD-180675_ref18","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/WAD.0b013e3181c53b00","article-title":"A single ascending dose study of bapineuzumab in patients with Alzheimer disease","volume":"24","author":"Black","year":"2010","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.3233\/JAD-180675_ref19","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jalz.2011.05.2353","article-title":"Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer\u2019s disease study cohorts from phase 3 trials of semagacestat and solanezumab","volume":"7","author":"Carlson","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-180675_ref20","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1212\/WNL.43.10.2073","article-title":"The clinical spectrum of cerebral amyloid angiopathy: Presentations without lobar hemorrhage","volume":"43","author":"Greenberg","year":"1993","journal-title":"Neurology"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-180675","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:08:30Z","timestamp":1777370910000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-180675"}},"subtitle":[],"editor":[{"given":"Katherine","family":"Bangen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,12,12]]},"references-count":20,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/jad-180675","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,12]]}}}